JP2022537773A5 - - Google Patents

Info

Publication number
JP2022537773A5
JP2022537773A5 JP2021576163A JP2021576163A JP2022537773A5 JP 2022537773 A5 JP2022537773 A5 JP 2022537773A5 JP 2021576163 A JP2021576163 A JP 2021576163A JP 2021576163 A JP2021576163 A JP 2021576163A JP 2022537773 A5 JP2022537773 A5 JP 2022537773A5
Authority
JP
Japan
Prior art keywords
compound according
aromatic
above formula
groups
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021576163A
Other languages
English (en)
Japanese (ja)
Other versions
JP7618599B2 (ja
JP2022537773A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2020/050864 external-priority patent/WO2020252598A1/en
Publication of JP2022537773A publication Critical patent/JP2022537773A/ja
Publication of JP2022537773A5 publication Critical patent/JP2022537773A5/ja
Priority to JP2025002658A priority Critical patent/JP2025069156A/ja
Application granted granted Critical
Publication of JP7618599B2 publication Critical patent/JP7618599B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021576163A 2019-06-21 2020-06-19 前立腺特異的膜抗原を標的とする放射性標識化合物 Active JP7618599B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025002658A JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962865088P 2019-06-21 2019-06-21
US62/865,088 2019-06-21
US202063006643P 2020-04-07 2020-04-07
US63/006,643 2020-04-07
PCT/CA2020/050864 WO2020252598A1 (en) 2019-06-21 2020-06-19 Radiolabeled compounds targeting the prostate-specific membrane antigen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025002658A Division JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Publications (3)

Publication Number Publication Date
JP2022537773A JP2022537773A (ja) 2022-08-29
JP2022537773A5 true JP2022537773A5 (cg-RX-API-DMAC10.html) 2023-06-26
JP7618599B2 JP7618599B2 (ja) 2025-01-21

Family

ID=74036930

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576163A Active JP7618599B2 (ja) 2019-06-21 2020-06-19 前立腺特異的膜抗原を標的とする放射性標識化合物
JP2025002658A Pending JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025002658A Pending JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Country Status (10)

Country Link
US (2) US11504441B2 (cg-RX-API-DMAC10.html)
EP (1) EP3986872A4 (cg-RX-API-DMAC10.html)
JP (2) JP7618599B2 (cg-RX-API-DMAC10.html)
KR (1) KR102998274B1 (cg-RX-API-DMAC10.html)
CN (2) CN119431260A (cg-RX-API-DMAC10.html)
AU (1) AU2020296488B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021025810A2 (cg-RX-API-DMAC10.html)
CA (1) CA3144094A1 (cg-RX-API-DMAC10.html)
IL (1) IL288960B2 (cg-RX-API-DMAC10.html)
WO (1) WO2020252598A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3136979A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
WO2022082312A1 (en) 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
US20240018110A1 (en) * 2020-12-16 2024-01-18 The University Of British Columbia Radiolabeled compounds targeting the prostate-specific membrane antigen
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
CA3208892A1 (en) * 2021-02-26 2022-09-01 Artur PINTO Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agent
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
WO2023083209A1 (zh) * 2021-11-10 2023-05-19 苏州瑞核医药科技有限公司 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用
CA3244865A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
WO2024016071A1 (en) * 2022-07-18 2024-01-25 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
IL319722A (en) * 2022-09-23 2025-05-01 Nuclidium Ag High purity radionuclides and their diagnostic and medical uses
CN118344391A (zh) * 2023-01-13 2024-07-16 浙江普利药业有限公司 一种新的用于硼中子捕获疗法的含硼化合物
CN116547293A (zh) * 2023-02-02 2023-08-04 北京师范大学 一种靶向前列腺特异性膜抗原的放射性金属配合物及其标记配体
EP4667019A1 (en) * 2023-02-16 2025-12-24 Norroy Bioscience Co., Ltd. Psma-targeted radiopharmaceutical, and synthesis and use thereof
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
CN116730983B (zh) * 2023-08-10 2023-11-03 山东大学 一种靶向前列腺特异性抗原的化合物及其制备方法与应用
EP4590664A1 (en) 2023-09-12 2025-07-30 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
EP4777499A1 (en) 2023-09-12 2026-07-22 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
CN117045828A (zh) * 2023-10-12 2023-11-14 北京先通国际医药科技股份有限公司 212Pb标记的放射性化合物在制备治疗前列腺癌药物中的用途
CN119101006B (zh) * 2024-09-05 2025-11-07 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性标记物及制法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US7563433B2 (en) 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
WO2005077967A1 (en) 2004-02-13 2005-08-25 The University Of British Columbia Radiolabeled compounds and compositions, their precursors and methods for their production
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
ES2684322T3 (es) 2006-11-08 2018-10-02 Molecular Insight Pharmaceuticals, Inc. Heterodímeros de ácido glutámico
WO2009002529A2 (en) 2007-06-26 2008-12-31 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
WO2009012596A1 (en) 2007-07-24 2009-01-29 The University Of British Columbia Substituted aryl-fluoroborates as imaging agents
ES2634894T3 (es) 2008-08-01 2017-09-29 The Johns Hopkins University Agentes de unión a PSMA y usos de los mismos
WO2012094334A1 (en) 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
MX2013010012A (es) 2011-03-01 2014-04-14 Ge Healthcare Ltd Analogos de octreotato radiomarcado como trazadores de tomografia por emision de positrones.
WO2013028791A1 (en) 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
US10011632B2 (en) 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140147381A1 (en) 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
CA2903281C (en) 2013-03-08 2022-11-29 The University Of British Columbia Substituted organofluoroborates as imaging agents
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
US10150804B2 (en) 2014-01-03 2018-12-11 British Columbia Cancer Agency Branch Compositions and methods for imaging cancer
WO2015135082A1 (en) 2014-03-13 2015-09-17 British Columbia Cancer Agency Branch Bradykinin receptor b1 targeting probes
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
EP3400229B1 (en) * 2016-01-10 2024-03-06 Provincial Health Services Authority 18/19f-labelled compounds which target the prostate specific membrane antigen
CN109982998A (zh) 2016-11-23 2019-07-05 癌靶技术有限责任公司 白蛋白结合psma抑制剂
CN106967152B (zh) 2017-03-28 2019-11-26 江苏省原子医学研究所 一种氟-18标记的化合物及其制备方法与应用
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
CA3066525A1 (en) * 2017-06-06 2018-12-13 The University Of Melbourne Radiopharmaceuticals, radioimaging agents, and uses thereof
AU2018352731B2 (en) 2017-10-22 2023-10-05 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
DK3723815T3 (da) 2017-12-11 2022-07-11 Univ Muenchen Tech PSMA ligander til billeddannelse og endoradioterapi
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
CN121534209A (zh) 2018-09-28 2026-02-17 海德堡大学 前列腺特异性膜抗原(psma)的标记抑制剂,其作为显像剂和药剂用于治疗表达psma的癌症的用途
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
CA3118223A1 (en) 2018-12-18 2020-06-25 Provincial Health Services Authority Dual mode 18f-labelled theranostic compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP3878208B2 (ja) 芳香族アミド化合物およびそれらのキレート
JP2024178310A5 (cg-RX-API-DMAC10.html)
RU2003108256A (ru) Производные тиофлавина, связывающие амилоид (варианты), и способ их получения (варианты), фармацевтическая композиция для визуализации in vivo отложений амилоида, способ обнаружения отложений амилоида (варианты), способ определения количества амилоида в биоптате или полученной посмертно ткани, спосооб распознавания боолезни альцгеймера
AU2018208538B2 (en) Chemical compounds for coating of nanostructures
TWI908773B (zh) 化合物及放射性標誌化合物
CA3144094A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
JP2024522174A5 (cg-RX-API-DMAC10.html)
JP2021527137A5 (cg-RX-API-DMAC10.html)
RU2003137593A (ru) Соединения на основе пептидов для направленной доставки к рецепторам интегринов
JP5690733B2 (ja) ビスホスホン酸誘導体及びその放射性金属核種標識体
JP2022539256A5 (cg-RX-API-DMAC10.html)
CN114729199A (zh) 化合物及使用了该化合物的荧光标记生物物质
CN116981486A (zh) 双模式放射性示踪剂和治疗剂
WO2023231452A1 (zh) 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备
JP2019507126A5 (cg-RX-API-DMAC10.html)
EP4263509A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
RU2014101255A (ru) Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение
RU2019118365A (ru) Хелатные соединения марганца на основе тетраазабицикло-макроцикла, подходящие в качестве визуализирующих агентов для MRI
JP2010529044A5 (cg-RX-API-DMAC10.html)
CA2705134C (en) Selective radiolabeling of biomolecules
RU2360701C2 (ru) Усовершенствованные конъюгаты n4 хелатообразующих агентов
JP2025161882A (ja) 放射性ハロゲン補欠部分および放射標識生体分子
JP2009534449A5 (cg-RX-API-DMAC10.html)
RU2013122649A (ru) Способ радиоактивного коньюгирования
RU2007110372A (ru) Агенты визуализации, ингибирующие металлопротеиназу